Belpointe Asset Management’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-1,136
Closed -$30.9K 2841
2023
Q1
$30.9K Sell
1,136
-545
-32% -$16.5K ﹤0.01% 2032
2022
Q4
$51.1K Buy
+1,681
New +$50.6K ﹤0.01% 1599

Other funds holding SBIO

Belpointe Asset Management's SBIO Position: Q2 2023 in Review

Belpointe Asset Management sold out of ALPS Medical Breakthroughs ETF (SBIO) in Q2 2023, closing a stake of 1,136 shares — an estimated $30.9K sold.

Belpointe Asset Management first reported a position in SBIO in Q4 2022 and held it in 2 quarters. The position peaked at $51.1K in Q4 2022. 41 funds tracked by Wall St. Rank hold SBIO as of Q2 2023.

  • Belpointe Asset Management reported no remaining ALPS Medical Breakthroughs ETF position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 1,136 ALPS Medical Breakthroughs ETF shares in Q2 2023, an estimated $30.9K.
  • Belpointe Asset Management first reported a position in ALPS Medical Breakthroughs ETF in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's ALPS Medical Breakthroughs ETF position peaked at $51.1K in Q4 2022.
  • 41 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.